A resident of Technopolis Moscow SEZ has begun to produce drugs for asthma and rare diseases


A resident of Technopolis Moscow special economic zone, which localized production at Alabushevo site, launched a workshop for the production of therapies for bronchial asthma, cardiovascular, rare, and hereditary diseases. This was announced by Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property and Land Relations.

“Generium-Next received the status of a resident of Moscow SEZ last year. The company rented a room with an area of about 500 sq. m at Alabushevo site, where it placed a workshop for the secondary packaging and production of drugs for the treatment of complications of bronchial asthma and orphan diseases, including Gaucher’s disease and cystic fibrosis,” Vladimir Efimov said.

He noted that the first batches of products have already been sent to pharmaceutical institutions. It is planned that the workshop will produce more than 150,000 units of products annually and will reach its full capacity by the end of 2024. “Today, the company’s customers are dozens of Moscow public and private medical institutions,” Vladimir Efimov said.

Generium-Next plans to build its own plant at Alabushevo site by 2024 and invest almost 5 billion rubles in it, the deputy mayor added. This will contribute to providing the healthcare system with modern genetically engineered medicines of domestic production, including those for severe diseases.

“After launching its own workshops, the company will produce substances and finished dosage forms, as well as primary and secondary packaging for medicines. It is planned to create at least 250 jobs at the enterprise,” Vladislav Ovchinsky, Head of the Investment and Industrial Policy Department, said.

The company implements a full cycle of production of biotechnological drugs, from the creation of a molecule to the launch of industrial production. It conducts research on individual drugs in collaboration with leading biotech companies and research institutes from around the world. The company is a leader in the orphan segment of the Russian pharmaceutical market.

“All the drugs produced by this resident of the Technopolis Moscow SEZ are included in the Ministry of Health’s VED list,” Gennady Degtev, General Director of Moscow SEZ, said.

Technopolis Moscow SEZ is a territory with a special legal status, with a preferential business regime for investors. The area of the five sites (Pechatniki, Alabushevo, Mikron, MIET, Angstrem) that house high-tech enterprises of the SEZ exceeds 223 hectares. The total area of the production buildings is 550,000 sq. m. The investments of companies that have localized production in Moscow SEZ exceeds 75 billion rubles.